Genefirst

GeneFirst is a private, commercial-stage molecular diagnostics company focused on developing and providing proprietary testing solutions. Its core technology platforms include ATOM-Seq (a next-generation sequencing capture chemistry for challenging samples), MMD (a high-sensitivity qPCR-based mutation detection assay), and MPA (a multiplex qPCR platform using high-resolution melt curve analysis). The company's marketed portfolio targets clear clinical needs in oncology (e.g., JAK2/ABL mutation kits), women's health (HPV DNA/RNA testing), and respiratory infections (multiplex pneumonia panels), positioning it as a specialized provider of fast, simple, and reliable molecular tests.

Proprietary molecular diagnostics platforms including: 1) ATOM-Seq, a next-generation sequencing capture chemistry for challenging samples (cfDNA, FFPE); 2) MMD, a high-sensitivity qPCR-based mutation detection assay; and 3) MPA, a multiplex qPCR platform using high-resolution melt curve analysis for differentiating multiple targets per channel.

Operates in a crowded molecular diagnostics sector. Competitors range from global giants like Roche, Qiagen, and Bio-Rad (offering broad platforms and kits) to niche players focusing on specific technologies like NGS or multiplex PCR. Differentiation hinges on the unique performance claims of ATOM-Seq for difficult samples and MPA for high-plex qPCR.